|
KMID : 1143920220260040363
|
|
Annals of Hepato-Biliary-Pancreatic Surgery
2022 Volume.26 No. 4 p.363 ~ p.374
|
|
|
Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”
|
|
Taboada Alvaro Gregorio Morales
Lominchar Pablo Lozano
Martinez Maria Fernandez
Alfonso Pilar Garcia
Martin Andres Munoz
Asencio Jose Manuel
|
|
|
Abstract
|
|
|
Backgrounds/Aims: To analyze the results of the neoadjuvant treatment of patients in our center with early pancreatic cancer.
Methods: Eighty-four patients with early pancreatic cancer (I?II) were included, of which 59 were considered “bioborderline” (carbohydrate antigen [CA] 19-9 > 37 U/L), and 25 were considered “non-bioborderline” (CA19-9 < 37 U/L). The R0 resection rate, presence of negative nodes, survival, and recurrence rates were analyzed in two groups, the NEO group (neoadjuvant + surgery) and the non-NEO group (upfront surgery).
Results: A 28.6% pathologic complete response was observed in the NEO group of the whole sample. The residual R0 was 85.7%, and nodes were negative in 78.6% of the patients in the NEO group of bioborderline patients. All non-bioborderline patients treated with neoadjuvant were R0, and no affected nodes were observed in any of them. The median overall survival (OS) in patients with elevated CA19-9 levels in the NEO group was 31.4 months vs. 13.1 months in the non-NEO (log-rank test p = 0.006), with a 62% relative reduction in the mortality rate (hazard ratio = 0.38, 95% confidence interval: 0.20?0.79; p = 0.008). The median OS in patients with normal CA19-9 levels in the NEO group was 65.9 months vs. 16.2 months in the non-NEO group, without statistically significant differences between the two but with a trend toward significance (log-rank test p = 0.08).
Conclusions: A neoadjuvant strategy seemed to improve local control and the survival of patients with early pancreatic cancer, both those with elevated CA19-9 and normal marker levels.
|
|
|
KEYWORD
|
|
|
Pancreatic neoplasms, Neoadjuvant therapy, Biomarkers, Early pancreatic cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|